News Headlines

  1. Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation For ABO-202 Gene Therapy Program In CLN1 Disease

    Abeona Therapeutics Inc. a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, announced recently that the FDA has granted Rare Pediatric Disease Designation for the ABO-202 program (AAV-CLN1), an AAV-based gene therapy for the treatment of CLN1 disease (infantile and late infantile onset Batten disease).

  2. TFS International Propels Momentum In Clinical Trials With GoBalto

    goBalto, Inc., the leading provider of cloud-based clinical study startup solutions, announced today that TFS International has chosen goBalto's Activate and Analyze solutions for starting clinical trials on a worldwide basis.

  3. OSE Immunotherapeutics Receives Approval In Europe To Resume Patient Accrual For Phase 3 Tedopi® Clinical Trial In Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment

    OSE Immunotherapeutics (ISIN:FR0012127173) (Mnémo:OSE), today announces that the Company has received a positive opinion in Europe through the Voluntary Harmonisation Procedure (VHP) to resume patient accrual in the global Tedopi® Phase 3 trial, based on the revised protocol already approved in the U.S.

  4. Worldwide Clinical Trials Acquires Continuum Clinical’s Late Stage Research Practice

    Worldwide Clinical Trials, Inc., (Worldwide) announced recently that the company has acquired the Late Stage research practice of Continuum Clinical, LLC, (Continuum) Northbrook, Illinois.

  5. Solid Biosciences Announces Clinical Hold On SGT-001 Phase I/II Clinical Trial For Duchenne Muscular Dystrophy

    Solid Biosciences Inc. today announced it has received notification from the U.S. Food and Drug Administration (FDA) that IGNITE DMD, its Phase I/II clinical trial for SGT-001 microdystrophin gene transfer in Duchenne muscular dystrophy (DMD), has been placed on Clinical Hold.

  6. New Advanced Reporting Options Enhance Experience For Clinical Research Professionals

    Crucial Data Solutions, Inc. announced today the latest update to their eClinical technology, which includes advanced reporting options. Both of Crucial Data Solutions’ electronic data capture (EDC) platforms, Clinical Studio and TrialKit, received system updates that added sophisticated reporting features to aid research professionals in tracking study progress through the life of a clinical trial.

  7. FDA Acceptance Of IND For Tyme To Begin Phase II Trial In Pancreatic Cancer

    Tyme Technologies, Inc. (NASDAQ:TYME) (“Tyme” or the “Company”) announced today that the U.S. Food and Drug Administration (“FDA”) has accepted its Investigational New Drug (“IND”) application allowing Tyme to initiate the planned Phase II clinical trial for SM-88 in pancreatic cancer.

  8. Majority Of Clinical Trials Planned In 2018 Belong To Oncology, Says GlobalData

    Cancer is one of the leading causes of morbidity and mortality across the world. Not surprisingly, oncology is going to be the top therapy areafor clinical trials planned to be initiated in 2018, according to GlobalData, a leading data and analytics company.

  9. American Liver Foundation And Antidote Launch Clinical Trial Matching Tool To Accelerate Liver Disease Research

    The American Liver Foundation (ALF), the nation’s largest patient advocacy organization for people with liver disease, announced today the launch of an online search tool to match liver disease patients with clinical trials that are appropriate for them.

  10. Diurnal Selects Worldwide Clinical Trials As Preferred CRO Provider

    Worldwide Clinical Trials, Inc., (Worldwide) announced today that Diurnal (Diurnal; AIM: DNL), a specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, has appointed Worldwide as its preferred provider of clinical trial services, initially to support the US clinical development of Chronocort® in both congenital adrenal hyperplasia (CAH) and adrenal insufficiency (AI).